Search
Research
Is Streptococcus pyogenes resistant or susceptible to trimethoprim- sulfamethoxazole?Streptococcus pyogenes is commonly believed to be resistant to trimethoprim-sulfamethoxazole (SXT), resulting in reservations about using SXT for skin and...
People
Professor Jonathan Carapetis AMInstitute Director; Head, Strep A Translation; Co-Founder of REACH
Research
Australian Strep A Vaccine Initiative (ASAVI)The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.
Research
BPG Formulation Preferences Study: Exploring patient, family and clinician reformulations preferences for BPGJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
Development of a longer acting formulation of Penicillin G for the treatment and prevention of acute rheumatic fever and rheumatic heart diseaseJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
News & Events
First week of school visits mark official launch of the SToP TrialThe The Kids Skin Health team has a busy six weeks ahead - visiting nine communities throughout the Kimberley region of WA as part of the first school surveillance activities for the SToP Trial.
Research
Skin Health Situational Analysis to inform skin disease control programs for the Kimberley - outcomesThe Skin Health Situational Analysis was conducted in 2017 with and for stakeholders in the Kimberley region as a precursor to the SToP Trial to highlight all that was already known prior to commencement in 2018. It was completed to be a resource for communities in the Kimberley who would like to de
Research
Comparison of three methods for the recovery of skin pathogens from impetigo swabs collected in a remote community of Northern Territory, AustraliaImmediate plating of impetigo swabs is the gold standard for bacterial recovery but is rarely feasible in remote regions.
Research
Prevention of bacterial complications of scabies using mass drug administration: A population-based, before-after trial in Fiji, 2018–2020Scabies is an important predisposing factor of impetigo which can lead to serious bacterial complications. Ivermectin-based mass drug administration can substantially reduce scabies and impetigo prevalence in endemic settings, but the impact on serious bacterial complications is not known.